JPH11500014A - ウイルス調製物、ベクター、免疫原、及びワクチン - Google Patents
ウイルス調製物、ベクター、免疫原、及びワクチンInfo
- Publication number
- JPH11500014A JPH11500014A JP8525488A JP52548896A JPH11500014A JP H11500014 A JPH11500014 A JP H11500014A JP 8525488 A JP8525488 A JP 8525488A JP 52548896 A JP52548896 A JP 52548896A JP H11500014 A JPH11500014 A JP H11500014A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- cells
- gene
- mutant
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.感染性の新しいウイルス粒子の生産のために本質的である選択された遺伝 子に関して欠損しており、免疫調節蛋白質をコードする異種遺伝材料を有するゲ ノムを有する変異ウイルスであって、該変異ウイルスが、通常の宿主細胞に感染 することができ、そしてその中での免疫調節蛋白質をコードする前記異種遺伝材 料の発現を引きおこすことができるが、前記変異ウイルスは、該ウイルスが前記 本質的なウイルス遺伝子の機能を供する遺伝子を有するように作製されそれを発 現することができる組換え補足性宿主細胞に感染する場合を除き、感染性の新し いウイルス粒子の生産を引きおこすことができず;前記免疫調節蛋白質をコード する前記異種遺伝材料の挿入の部位が、好ましくは前記選択された本質的なウイ ルスゲノムにおける欠損の部位であり、例えばそれで治療された被検体において 免疫応答を発生することにおける診断又は予防に用いるためであることを特徴と する変異ウイルス。 2.前記欠損がウイルスのグリコプロテイン遺伝子においてあることを特徴と する請求項1に記載の変異ウイルス。 3.ヘルペスウイルスの変異体であることを特徴とする請求項1に記載の変異 ウイルス。 4.単純ヘルペスウイルス(HSV)の変異体であることを特徴とする請求項1に 記載の変異ウイルス。 5.前記欠損が、ヘルペスウイルスのグリコプロテインにおいて、例えばグリ コプロテインgH,gD,gB又はgLに対応する遺伝子においてあることを特徴とする 請求項3又は4に記載の変異ウイルス。 6.前記異種遺伝材料が、サイトカイン、ケモカイン、補体構成物、免疫系補 助分子、及びそれらのためのヒト又は非ヒト動物特異 性のレセプターから選択される蛋白質をコードすることを特徴とする先の請求項 のいずれかに記載の変異ウイルス。 7.前記異種遺伝材料が、GM-CSF,IL-2,IL-12,OX40,OX40L(gp34)、及びC D40L から選択される蛋白質をコードすることを特徴とする先の請求項のいずれ かに記載の変異ウイルス。 8.それで処理される被検体において免疫応答を発生させることにおいて予防 又は治療に用いるための免疫原としての請求項1〜7のいずれかに記載の変異ウ イルスの使用。 9.前記免疫応答が前記変異ウイルスによりコードされる異種抗原に対してで あることを特徴とする請求項8に記載の使用。 10.腫瘍療法における治療又は予防に用いるためのワクチンのような免疫原の 調製における請求項1〜7のいずれかに記載の変異ウイルスの使用。 11.(例えばウイルス特異的)細胞毒性T細胞の試験管内増殖(expansion)に おける請求項1〜7のいずれかに記載の変異ウイルスの使用。 12.治療又は予防的矯正遺伝子療法のための請求項1〜7のいずれかに記載の 変異ウイルスの使用。 13.治療されるヒト又は非ヒト動物被検体に免疫刺激を供するための請求項1 〜7のいずれかに記載の変異ウイルスを用いる方法であって、 (i)ウイルスベクターの感染後に治療されるべき被検体に免疫刺激を供する ことができる細胞の調製物に、前記変異ウイルスを生体外で接触させるステップ と、 (ii)その感染した細胞を用いて、前記治療されるべき被検体に免疫刺激を供 するステップと、 を含むことを特徴とする方法。 14.前記感染した細胞が、例えば投与前の不活性化の後、例えば照射の後に、 ワクチンとしての前記感染した細胞の直接の投与により治療されるべき被検体に 、免疫刺激を供するのに用いられることを特徴とする請求項13に記載の方法。 15.前記感染した細胞が、治療されるべき被検体の免疫系の細胞のような免疫 コンピテント細胞を生体外で刺激するための前記細胞の使用により治療されるべ き被検体に、免疫刺激を供するために用いられ、次に例えばウイルス又はウイル ス感染細胞の同時投与なしで、免疫コンピテント細胞の再投与することを特徴と する請求項13に記載の方法。 16.前記ウイルスベクターに生体外で感染した細胞が自己由来細胞であること を特徴とする請求項15に記載の方法。 17.前記ウイルスベクターに生体外で感染した細胞が、例えば腫瘍細胞系の細 胞を含む、異種細胞であることを特徴とする請求項15に記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9503395.7 | 1995-02-21 | ||
GBGB9503395.7A GB9503395D0 (en) | 1995-02-21 | 1995-02-21 | Viral,preparations,immunogens,and vaccines |
GB9515557.8 | 1995-07-28 | ||
GBGB9515557.8A GB9515557D0 (en) | 1995-07-28 | 1995-07-28 | Viral preparation,immunogens and vacciness |
GBGB9603322.0A GB9603322D0 (en) | 1996-02-16 | 1996-02-16 | Viral preparations,immunogens and vaccines |
GB9603322.0 | 1996-02-16 | ||
PCT/GB1996/000385 WO1996026267A1 (en) | 1995-02-21 | 1996-02-21 | Viral preparations, vectors, immunogens, and vaccines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006336186A Division JP2007130022A (ja) | 1995-02-21 | 2006-12-13 | ウイルス調製物、ベクター、免疫原、及びワクチン |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11500014A true JPH11500014A (ja) | 1999-01-06 |
Family
ID=27267593
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8525488A Pending JPH11500014A (ja) | 1995-02-21 | 1996-02-21 | ウイルス調製物、ベクター、免疫原、及びワクチン |
JP2006336186A Pending JP2007130022A (ja) | 1995-02-21 | 2006-12-13 | ウイルス調製物、ベクター、免疫原、及びワクチン |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006336186A Pending JP2007130022A (ja) | 1995-02-21 | 2006-12-13 | ウイルス調製物、ベクター、免疫原、及びワクチン |
Country Status (9)
Country | Link |
---|---|
US (4) | US6287557B1 (ja) |
EP (2) | EP1683858A3 (ja) |
JP (2) | JPH11500014A (ja) |
AT (1) | ATE324435T1 (ja) |
AU (1) | AU711121B2 (ja) |
CA (1) | CA2211743A1 (ja) |
DE (1) | DE69636068T2 (ja) |
ES (1) | ES2264136T3 (ja) |
WO (1) | WO1996026267A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU711121B2 (en) * | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
US6344445B1 (en) | 1995-10-19 | 2002-02-05 | Cantab Pharmaceutical Research Limited | Herpes virus vectors and their uses |
EP0950097A2 (en) * | 1996-12-27 | 1999-10-20 | Instituto de Investigaciones Bioquimicas Fundacion Campomar | Compositions and methods for tumour therapy |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
US6277621B1 (en) | 1998-02-26 | 2001-08-21 | Medigene, Inc. | Artificial chromosome constructs containing foreign nucleic acid sequences |
GB9816761D0 (en) | 1998-07-31 | 1998-09-30 | Phogen Limited | Herpesvirus preparations and their uses |
GB9816775D0 (en) * | 1998-07-31 | 1998-09-30 | Efstathiou Stacey | Herpesviral vectors for gene delivery |
BR9912671A (pt) * | 1998-08-07 | 2001-05-02 | Univ Washington | Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização |
EP1038952A3 (en) * | 1998-12-09 | 2001-06-27 | Pfizer Products Inc. | Processes for preparation of Marek's Disease Virus using continuous avian cell lines |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
JP2003501445A (ja) * | 1999-06-08 | 2003-01-14 | ユーエイビー リサーチ ファンデーション | 外来遺伝子を発現するヘルペス単純ウイルスおよびそれによる癌の治療方法 |
US6764675B1 (en) * | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
GB0013817D0 (en) * | 2000-06-06 | 2000-07-26 | Univ Nottingham Trent | Method for treating cells |
US20030188326A1 (en) * | 2000-11-03 | 2003-10-02 | Dana Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof |
AU2002218006A1 (en) | 2000-11-03 | 2002-05-15 | Dana Farber Cancer Institute | Compositions and methods for the diagnosis of cancer |
SG159381A1 (en) | 2001-10-10 | 2010-03-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
SE0201701D0 (sv) * | 2002-06-05 | 2002-06-05 | Gotovax Ab | Treatment of epithelial tumors and infections |
AU2003295502A1 (en) | 2002-11-12 | 2004-06-03 | Yucheng Chang | Adenoviral vector vaccine |
EP1687334B1 (en) | 2003-11-24 | 2014-01-08 | MicroVAX, LLC | Mucin antigen vaccine |
US8828957B2 (en) * | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
US8865185B2 (en) | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
US8871223B2 (en) * | 2006-09-08 | 2014-10-28 | The Trustees Of The University Of Pennsylvania | HSV-1 and HSV-2 vaccines and methods of use thereof |
CN101616688B (zh) * | 2006-12-28 | 2013-12-11 | 宾夕法尼亚大学理事会 | 单纯疱疹病毒联合亚单位疫苗及其使用方法 |
US10478490B2 (en) | 2006-12-28 | 2019-11-19 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
US20120289760A1 (en) * | 2010-01-27 | 2012-11-15 | Hill Ann B | Cytomegalovirus-based immunogenic preparations |
EP2550362B1 (en) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
EP3351636B1 (en) | 2010-05-14 | 2020-07-01 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors encoding a heterologous antigen isolated from a paramyxoviridae virus and uses thereof |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
US9783823B2 (en) | 2013-03-05 | 2017-10-10 | Oregon Health & Science University | Cytomegalovirus vectors enabling control of T cell targeting |
SG11201700315YA (en) | 2014-07-16 | 2017-02-27 | Univ Oregon Health & Science | Human cytomegalovirus comprising exogenous antigens |
EP3256595A4 (en) | 2015-02-10 | 2018-09-26 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
MA43285A (fr) | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11306292B2 (en) | 2017-05-15 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
CH682669A5 (fr) | 1989-03-08 | 1993-10-29 | Health Research Inc | Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants. |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
AU8533291A (en) * | 1990-09-18 | 1992-04-15 | Lucas Industries Public Limited Company | Fuel injection nozzles |
JP3895366B2 (ja) * | 1990-09-25 | 2007-03-22 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウィルス ワクチン |
US5837261A (en) * | 1990-09-25 | 1998-11-17 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
US5665362A (en) * | 1990-09-25 | 1997-09-09 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
US5849571A (en) * | 1990-10-10 | 1998-12-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Latency active herpes virus promoters and their use |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
HU218849B (hu) | 1992-06-01 | 2000-12-28 | American Cyanamid Co. | Gazdaszervezetről gazdaszervezetre a környezetben csökkent terjedési képességgel rendelkező rekombináns bakulovirus és eljárás előállítására |
ATE288483T1 (de) | 1992-07-30 | 2005-02-15 | Akzo Nobel Nv | Nicht-verbreitendes lebendes herpesvirusvakzin |
CA2141574C (en) * | 1992-07-31 | 2009-11-24 | David Knipe | Herpesvirus vaccines |
US5658724A (en) * | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
US20020009462A1 (en) * | 1992-07-31 | 2002-01-24 | David M. Knipe | Herpesvirus replication defective mutants |
US5661033A (en) * | 1992-11-25 | 1997-08-26 | The Board Of Trustees Of The Leland Stanford Junior University | Gene transfer using herpes virus vectors as a tool for neuroprotection |
WO1994021807A2 (en) * | 1993-03-19 | 1994-09-29 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
WO1994024296A2 (en) * | 1993-04-19 | 1994-10-27 | University Of Saskatchewan | Recombinant bovine herpesvirus type 1 vaccines |
US5910488A (en) * | 1993-06-07 | 1999-06-08 | Vical Incorporated | Plasmids suitable for gene therapy |
WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
US5763217A (en) * | 1993-11-10 | 1998-06-09 | University Of British Columbia | Method of using, process of preparing and composition comprising recombinant herpesvirus vectors |
JPH09503920A (ja) * | 1993-11-18 | 1997-04-22 | チロン ビアジーン,インコーポレイティド | 条件致死遺伝子を利用する組成物及び方法 |
US5693531A (en) * | 1993-11-24 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vector systems for the generation of adeno-associated virus particles |
US5763416A (en) * | 1994-02-18 | 1998-06-09 | The Regent Of The University Of Michigan | Gene transfer into bone cells and tissues |
US5585096A (en) * | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5872005A (en) * | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
AU711121B2 (en) * | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
WO1996029421A1 (en) * | 1995-03-23 | 1996-09-26 | Cantab Pharmaceuticals Research Limited | Vectors for gene delivery |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
-
1996
- 1996-02-21 AU AU47263/96A patent/AU711121B2/en not_active Ceased
- 1996-02-21 JP JP8525488A patent/JPH11500014A/ja active Pending
- 1996-02-21 AT AT96903115T patent/ATE324435T1/de not_active IP Right Cessation
- 1996-02-21 DE DE69636068T patent/DE69636068T2/de not_active Expired - Lifetime
- 1996-02-21 US US08/604,165 patent/US6287557B1/en not_active Expired - Fee Related
- 1996-02-21 CA CA002211743A patent/CA2211743A1/en not_active Abandoned
- 1996-02-21 ES ES96903115T patent/ES2264136T3/es not_active Expired - Lifetime
- 1996-02-21 WO PCT/GB1996/000385 patent/WO1996026267A1/en active IP Right Grant
- 1996-02-21 EP EP06007480A patent/EP1683858A3/en not_active Withdrawn
- 1996-02-21 EP EP96903115A patent/EP0811057B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/765,870 patent/US20020150562A1/en not_active Abandoned
- 2001-07-27 US US09/917,176 patent/US20030091535A1/en not_active Abandoned
-
2004
- 2004-09-14 US US10/941,295 patent/US20050118192A1/en not_active Abandoned
-
2006
- 2006-12-13 JP JP2006336186A patent/JP2007130022A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2264136T3 (es) | 2006-12-16 |
DE69636068T2 (de) | 2006-11-30 |
EP0811057A1 (en) | 1997-12-10 |
AU711121B2 (en) | 1999-10-07 |
AU4726396A (en) | 1996-09-11 |
US6287557B1 (en) | 2001-09-11 |
US20020150562A1 (en) | 2002-10-17 |
EP0811057B1 (en) | 2006-04-26 |
US20050118192A1 (en) | 2005-06-02 |
EP1683858A2 (en) | 2006-07-26 |
JP2007130022A (ja) | 2007-05-31 |
EP1683858A3 (en) | 2006-08-02 |
DE69636068D1 (de) | 2006-06-01 |
WO1996026267A1 (en) | 1996-08-29 |
ATE324435T1 (de) | 2006-05-15 |
CA2211743A1 (en) | 1996-08-29 |
US20030091535A1 (en) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11500014A (ja) | ウイルス調製物、ベクター、免疫原、及びワクチン | |
US5928913A (en) | Vectors for gene delivery | |
US6344445B1 (en) | Herpes virus vectors and their uses | |
JP5492418B2 (ja) | ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法 | |
US8119118B2 (en) | Helper virus-free herpesvirus amplicon particles and uses thereof | |
CA2356937A1 (en) | Recombinant herpes simplex virus useful for treating neoplastic disease | |
AU2002246625A1 (en) | Helper virus-free herpes virus amplicon particles and uses thereof | |
ZA200501193B (en) | Non-human herpesviruses as vectors. | |
EP0856062A2 (en) | Herpesvirus vectors and their uses | |
Raggo et al. | Expression of Bovine Interleukin-1β in a Bovine Herpesvirus-1 Vector: In VitroAnalysis | |
US20030083289A1 (en) | Herpesvirus vectors and their uses | |
AU763297B2 (en) | Herpesvirus vectors and their uses | |
AU4445599A (en) | Viral preparations, vectors, immunogens, and vaccines | |
MXPA98002999A (en) | Vectors of the herpes virus and its u | |
AU2013204991A1 (en) | Viral gene products and methods for vaccination to prevent viral associated diseases | |
WO1996016164A1 (en) | Viral preparations, immunogens, and vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060616 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060815 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061213 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070125 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070208 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081219 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090109 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100223 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100226 |